TY - JOUR
T1 - Use of a new ALS specific respiratory questionnaire
T2 - the ARES score
AU - Heiman-Patterson, Terry D.
AU - Sherman, Michael S.
AU - Yu, Daohai
AU - Jackson, Carlayne E.
AU - George, Asha
AU - Kasarskis, Edward J.
AU - Heiman-Patterson, Terry
AU - Sherman, Michael S.
AU - Mitchell, Melonie
AU - Sattazahn, Roseanne
AU - Feldman, Sara
AU - Scelsa, Stephen N.
AU - Imperato, Theresa
AU - Shefner, Jeremy M.
AU - Watson, Mary Lou
AU - Rollins, Yvonne
AU - Cumming, John
AU - Newman, Dan
AU - Foley, Helen
AU - Verma, Ashok
AU - Koggan, Donald
AU - Steele, Julie
AU - Jackson, Carlayne
AU - Kittrell, Pam
AU - Kasarskis, Edward J.
AU - Wells, Stephen
AU - Vanderpool, Kathryn
AU - Shrestha, Christie
AU - Taylor, Deborah
AU - Mendiondo, Marta
AU - Kryscio, Richard
AU - Healey, Margaret
AU - Sams, Marsha
AU - Thompson, Megan
AU - Mitsumoto, Hiroshi
AU - Bell, Daniel
AU - Tandan, Rup
AU - Potter, Chris
AU - Matthews, Dwight
AU - Bromberg, Mark
AU - Davis, Summer
AU - Simmons, Zachary
AU - Stephens, Beth
AU - Brothers, Ally
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Objective: To develop an ALS respiratory symptom scale (ARES) and evaluate how ARES compares to Medical Research Council Modified Dyspnea Scale (MRC), Borg dyspnea scale, and respiratory subscores from ALSFRS-R (ALSFRS-Resp) in detecting respiratory symptoms, correlation with pulmonary function and ALSFRS-R, and deterioration of pulmonary function and ALSFRS-R over time. Methods: The ARES scale consists of 9 questions addressing dyspnea during activities and 3 questions addressing symptoms of worsening pulmonary function. 153 subjects with ALS completed MRC, Borg, ALSFRS-R, and ARES questionnaires at baseline, 16, 32, and 48 weeks, and spirometry at baseline. 73 of these subjects had spirometry, maximum inspiratory (MIP) and expiratory pressures (MEP), nasal inspiratory pressure (SNIP), and maximum voluntary ventilation (MVV) measured at each visit. Sensitivity of each scale and correlations between symptom scores, pulmonary function, and ALSFRS-R were evaluated at baseline and over the study duration. Results and conclusions: ARES was more sensitive than MRC, Borg and ALSFRS-Resp scales at baseline and for detecting changes at 16 and 32 weeks. ARES and ALSFRS-Resp correlated significantly with vital capacity at baseline, but Borg and MRC did not. Only ALSFRS-Resp correlated with respiratory pressures. Changes in ALSFRS-Resp and ARES both correlated with vital capacity decline; however, changes in ARES had superior correlation with respiratory pressure decline. Comparisons between telephone and in-person administration of ARES met criteria for satisfactory test-retest correlation in different settings one week apart. These findings suggest that the ARES may be more useful in monitoring symptom progression in ALS than other available scales.
AB - Objective: To develop an ALS respiratory symptom scale (ARES) and evaluate how ARES compares to Medical Research Council Modified Dyspnea Scale (MRC), Borg dyspnea scale, and respiratory subscores from ALSFRS-R (ALSFRS-Resp) in detecting respiratory symptoms, correlation with pulmonary function and ALSFRS-R, and deterioration of pulmonary function and ALSFRS-R over time. Methods: The ARES scale consists of 9 questions addressing dyspnea during activities and 3 questions addressing symptoms of worsening pulmonary function. 153 subjects with ALS completed MRC, Borg, ALSFRS-R, and ARES questionnaires at baseline, 16, 32, and 48 weeks, and spirometry at baseline. 73 of these subjects had spirometry, maximum inspiratory (MIP) and expiratory pressures (MEP), nasal inspiratory pressure (SNIP), and maximum voluntary ventilation (MVV) measured at each visit. Sensitivity of each scale and correlations between symptom scores, pulmonary function, and ALSFRS-R were evaluated at baseline and over the study duration. Results and conclusions: ARES was more sensitive than MRC, Borg and ALSFRS-Resp scales at baseline and for detecting changes at 16 and 32 weeks. ARES and ALSFRS-Resp correlated significantly with vital capacity at baseline, but Borg and MRC did not. Only ALSFRS-Resp correlated with respiratory pressures. Changes in ALSFRS-Resp and ARES both correlated with vital capacity decline; however, changes in ARES had superior correlation with respiratory pressure decline. Comparisons between telephone and in-person administration of ARES met criteria for satisfactory test-retest correlation in different settings one week apart. These findings suggest that the ARES may be more useful in monitoring symptom progression in ALS than other available scales.
KW - Ventilation
KW - amyotrophic lateral sclerosis
KW - dyspnea
KW - vital capacity
UR - http://www.scopus.com/inward/record.url?scp=85113388424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113388424&partnerID=8YFLogxK
U2 - 10.1080/21678421.2021.1910307
DO - 10.1080/21678421.2021.1910307
M3 - Article
C2 - 34348538
AN - SCOPUS:85113388424
SN - 2167-8421
VL - 22
SP - 48
EP - 53
JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
IS - S1
ER -